Probability of blindness from glaucoma nearly halved since 1980

Article

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study recently published in Ophthalmology.

San Francisco, CA- The probability of blindness due to glaucoma has decreased by nearly half since 1980, according to a study recently published in Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease but caution that a significant proportion of patients still progress to blindness. 

Significant changes in diagnostic criteria, new therapies and tools, as well as improvements in glaucoma management techniques, have benefited individual patients; however, their effect on the rates of visual impairment on a population level has remained unclear. This study, conducted by a team based at the Mayo Clinic, was the first to assess long-term changes in the risk of progression to blindness and the population incidence of glaucoma-related blindness. By identifying epidemiologic trends in glaucoma, the researchers hope to gain insight into best practices for the distribution of health and medical resources, as well as management approaches for entire populations.

The researchers reviewed every incident case (857 cases total) of open-angle glaucoma (OAG) diagnosed from 1965 to 2009 in Olmsted County, MN. They found that the 20-year probability and the population incidence of blindness due to OAG in at least one eye had decreased from 25.8% for subjects diagnosed between 1965 and 1980 to 13.5% for those diagnosed between 1981 and 2000. The population incidence of blindness within 10 years of diagnosis also decreased from 8.7 per 100,000 to 5.5 per 100,000 for those groups, respectively. Yet, 15% of the patients diagnosed in the more recent timeframe still progressed to blindness.

"Despite this good news, the rate at which people continue to go blind due to OAG is still unacceptably high. This is likely due to late diagnosis and our incomplete understanding of glaucoma, so it is critical that research into this devastating disease continues, and all eye care providers be vigilant in looking for early signs of glaucoma during routine exams,” says Arthur J. Sit, MD, associate professor of ophthalmology at the Mayo Clinic College of Medicine and lead researcher for the study.

Recent Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr Nate Lighthizer discusses his 2024 Vision Expo West presentations
Jeffry Gerson, OD, FAAO, chats with Optometry Times about his talks about retina conditions at Vision Expo West
Danica Marrelli, OD, FAAO, AAO Dip, talks OCT and glaucoma
Ben Casella, OD, FAAO, talks 2024 EyeCon's networking and education opportunities
EyeCon Co-chair Oluwatosin U. Smith, MD talks passion for research and education in ophthalmology
Lorraine Provencher, MD, presenting slides
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
© 2024 MJH Life Sciences

All rights reserved.